Influence of pregnancy on outcomes of inflammatory bowel disease and treatment discontinuation

BACKGROUND Treatment of inflammatory bowel diseases (IBDs) is challenging due to the maintenance of remission and associated fetal safety concerns during pregnancy. While existing literature emphasizes the importance of achieving remission prior to conception, optimal management of IBD during pregnancy remains underexplored, especially regarding medication continuation and efficacy. AIM To evaluate the effect of treatment discontinuation on disease activation and pregnancy outcomes in a cohort of patients with IBD. METHODS This observational study was performed with pregnant patients with IBD between March 2019 and June 2023. Clinical features, treatment details, disease activation and outcomes were collected and analyzed. RESULTS A total of 57 pregnant woman was included, of whom 37 (64.9%) had ulcerative colitis (UC) while 20 (35.1%) had Crohn’s disease (CD). Before pregnancy, medical treatments for UC patients included mesalazine in 29 (78.4%) patients, thiopurine in 20 (54.1%) and biologic therapy in 6 (16.2%). Among the CD patients, 13 (65%) received biologic therapy and 7 (35%) received thiopurine. The most commonly prescribed biologic agent was infliximab for both diseases. During pregnancy, 16 (28.1%) patients, including 6 (18.8%) with UC and 10 (50%) with CD, had a history of treatment discontinuation. Thirteen (81%) medications were discontinued in line with the patient’s preference, with the vast majority of these discontinuations occurring immediately after confirmation of pregnancy rather than during the preconception planning phase. Notably, the majority of cases of patients discontinuing their treatment independently occurred prior to any structured medical counseling regarding the safety of IBD medications during pregnancy. Disease activation occurred for 25 (43.9%) patients, including 10 (50%) with CD and 15 (40.5%) with UC. Twelve (48%) patients required steroids due to activation. There were 54 (94.7%) live births and no statistically significant difference in the live birth rate according to whether disease activation developed or not [23 (92%) vs 31 (96.9%), P = 0.576]. The abortion rate was not associated with disease activation (P > 0.05). No serious infections occurred in the first month following birth. CONCLUSION The discontinuation of medical treatment during pregnancy at the patient’s discretion was significantly correlated with disease exacerbations, particularly in patients with UC, and subsequent salvage steroid treatment. These findings underscore the vital role of patient counseling prior to and during pregnancy, with the objective of ensuring medication compliance and optimizing maternal and fetal outcomes.

Authors

Publication Details

Journal
World Journal of Gastroenterology
Published
2026-11-21
DOI
https://doi.org/10.3748/wjg.120573
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Influence of pregnancy on outcomes of inflammatory bowel disease and treatment discontinuation

Oguz Ozturk, Ali Atay, İlhami Yüksel, Muhammed Bahaddin Durak et al.
3 links
World Journal of Gastroenterology
Pregnancy and Medication Impact
article

Influence of pregnancy on outcomes of inflammatory bowel disease and treatment discontinuation

Oguz Ozturk, Ali Atay, İlhami Yüksel, Muhammed Bahaddin Durak, Yavuz Çağır, Mücahit Ergül, Emir Tuğrul Keskin, Kadir Can Acun, Eren Yilmaz
article en

Abstract

BACKGROUND Treatment of inflammatory bowel diseases (IBDs) is challenging due to the maintenance of remission and associated fetal safety concerns during pregnancy. While existing literature emphasizes the importance of achieving remission prior to conception, optimal management of IBD during pregnancy remains underexplored, especially regarding medication continuation and efficacy. AIM To evaluate the effect of treatment discontinuation on disease activation and pregnancy outcomes in a cohort of patients with IBD. METHODS This observational study was performed with pregnant patients with IBD between March 2019 and June 2023. Clinical features, treatment details, disease activation and outcomes were collected and analyzed. RESULTS A total of 57 pregnant woman was included, of whom 37 (64.9%) had ulcerative colitis (UC) while 20 (35.1%) had Crohn’s disease (CD). Before pregnancy, medical treatments for UC patients included mesalazine in 29 (78.4%) patients, thiopurine in 20 (54.1%) and biologic therapy in 6 (16.2%). Among the CD patients, 13 (65%) received biologic therapy and 7 (35%) received thiopurine. The most commonly prescribed biologic agent was infliximab for both diseases. During pregnancy, 16 (28.1%) patients, including 6 (18.8%) with UC and 10 (50%) with CD, had a history of treatment discontinuation. Thirteen (81%) medications were discontinued in line with the patient’s preference, with the vast majority of these discontinuations occurring immediately after confirmation of pregnancy rather than during the preconception planning phase. Notably, the majority of cases of patients discontinuing their treatment independently occurred prior to any structured medical counseling regarding the safety of IBD medications during pregnancy. Disease activation occurred for 25 (43.9%) patients, including 10 (50%) with CD and 15 (40.5%) with UC. Twelve (48%) patients required steroids due to activation. There were 54 (94.7%) live births and no statistically significant difference in the live birth rate according to whether disease activation developed or not [23 (92%) vs 31 (96.9%), P = 0.576]. The abortion rate was not associated with disease activation (P > 0.05). No serious infections occurred in the first month following birth. CONCLUSION The discontinuation of medical treatment during pregnancy at the patient’s discretion was significantly correlated with disease exacerbations, particularly in patients with UC, and subsequent salvage steroid treatment. These findings underscore the vital role of patient counseling prior to and during pregnancy, with the objective of ensuring medication compliance and optimizing maternal and fetal outcomes.

World Journal of GastroenterologyVol. 32(43)
Good health and well-being
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon